Amgen, Genetics Institute news

Thousand Oaks, Calif.-based AMGN asked the U.S. District Court for the District of Massachusetts for a declaratory judgment that GENIZ's U.S. patent No. 5,322,837 isn't infringed by AMGN and is invalid and unenforceable. The patent, which was issued to GENIZ is June, covers homogeneous erythropoietin.

AMGN also wants the court to declare that any dispute over the '837 patent was resolved by prior litigation (see Analyst Picks & Changes). ...